News

Dr. Yu Qiang of CGeneTech was interviewed by "Science and Technology Source Power" of First Financial Group

  • Categories:Media
  • Author:
  • Origin:科创源动力
  • Time of issue:2021-12-20
  • Views:0

(Summary description)Recently, the "Source Dynamics of Science and Technology Innovation" column presented by China Business News and WeChat Bank went to Suzhou Industrial Park to explore the upgrading path of "Made in Suzhou" and analyze the "source dynamics" behind the rapid development of Suzhou's science and technology innovation enterprises together with Yang Yudong, Editor-in-Chief of China Business News, Wang Qiangbin, Executive Vice Director of Suzhou Institute of Nanotechnology and Nanobiont, Chinese Academy of Sciences, Li Wei, Deputy Director of Institute of Applied Economic Research, Shanghai Academy of Social Sciences, Fei Jianjiang, Managing Partner of Suzhou Industrial Park Yuanhe Origin Venture Capital Co.

Dr. Yu Qiang of CGeneTech was interviewed by "Science and Technology Source Power" of First Financial Group

(Summary description)Recently, the "Source Dynamics of Science and Technology Innovation" column presented by China Business News and WeChat Bank went to Suzhou Industrial Park to explore the upgrading path of "Made in Suzhou" and analyze the "source dynamics" behind the rapid development of Suzhou's science and technology innovation enterprises together with Yang Yudong, Editor-in-Chief of China Business News, Wang Qiangbin, Executive Vice Director of Suzhou Institute of Nanotechnology and Nanobiont, Chinese Academy of Sciences, Li Wei, Deputy Director of Institute of Applied Economic Research, Shanghai Academy of Social Sciences, Fei Jianjiang, Managing Partner of Suzhou Industrial Park Yuanhe Origin Venture Capital Co.

  • Categories:Media
  • Author:
  • Origin:科创源动力
  • Time of issue:2021-12-20
  • Views:0

  Recently, the "Source Dynamics of Science and Technology Innovation" column presented by China Business News and WeChat Bank went to Suzhou Industrial Park to explore the upgrading path of "Made in Suzhou" and analyze the "source dynamics" behind the rapid development of Suzhou's science and technology innovation enterprises together with Yang Yudong, Editor-in-Chief of China Business News, Wang Qiangbin, Executive Vice Director of Suzhou Institute of Nanotechnology and Nanobiont, Chinese Academy of Sciences, Li Wei, Deputy Director of Institute of Applied Economic Research, Shanghai Academy of Social Sciences, Fei Jianjiang, Managing Partner of Suzhou Industrial Park Yuanhe Origin Venture Capital Co.1

  

With a complete set of services from policy, talent, information, to capital, Suzhou has attracted many high-tech enterprises. Dr. Yu Qiang, CEO of Centec Biomedical Technology (Suzhou) Co., Ltd. said in an interview with the columnist that besides being very livable, Suzhou is also very considerate to talents and precise services, and can consider various pain points of biomedical innovative enterprises in the process of growth and provide various policy benefits.

  Innovation starts with industry, and industry changes because of innovation. Suzhou's "manufacturing gene", which has been passed down from generation to generation, is driving the engine of innovation, drawing the blueprint for industrial upgrading and gathering more and more talents.

  This is the best expression of the value and power of finance, which supports the growth of enterprises, drives the development of industries, and supports economic growth. With the combined efforts of government, capital, talents and industry, the innovation power of a city will continue to surge.

  Link to original article: First Financial. From a thousand-year old capital to a city of innovation, decoding the driving force of science and innovation behind Suzhou.  https://m.yicai.com/news/101262719.html,2021-12-19

The

The listing application of Shengshi Tyco's new hypoglycemic drug Shenggliptin was accepted

Today, Shengshi Tyco has accepted the marketing application (NDA) of Shenggliptin, a DPP-4 inhibitor, submitted to the National Drug Administration (NMPA) for the treatment of type 2 diabetes.
2023-02-02
Quantity

"Quantity" Half Achieves Double Prosperity: Tyco's Class 1 New Hypoglycemic Drug Shenggliptin Uncovers Blindness Data

Today, Shengshi Tyco has completed a key clinical study on a class 1 new hypoglycemic drug under development: phase III clinical trial of DPP-4 inhibitor shenggliptin in the treatment of type 2 diabetes. A dose of 50mg can reach the preset end point of the trial. A therapeutic dose of "half the dose" will further improve the safety of this drug and is expected to become the best hypoglycemic drug in the same class.
2022-10-17

Contact Us

Add:Room 101, Bld C11, 218 Xinghu Rd,Suzhou industrial Park,China, 215123

Tel: +86-512-62956960(Recruitment)

         +86-512-62956961(marketing)

Copyright © 2022  CGeneTech (Suzhou, China) Co., Ltd.  All rights reserved.  苏ICP备2022006552号-1  Powered by 300.cn  SEO